Beam Sickle Cell Therapy Meets Pivotal Goals Ahead of Planned BLA

Beam Therapeutics (BEAM ) announced on November 10, 2026 that ristoglogene autogetemcel (risto-cel), its investigational one-time cell therapy for sickle cell disease, met the primary efficacy and safety endpoints in a prespecified interim analysis of the BEACON Phase 1/2 trial, supporting a planned U.S. Biologics License Application submission as early as the end of 2026.

BEACON achieved its primary efficacy endpoint, VF12, defined as freedom from severe vaso-occlusive crises for at least 12 consecutive months, based on independently adjudicated results. All primary safety endpoints and all secondary efficacy endpoints were also met, including freedom from inpatient hospitalization for severe crises for at least 12 consecutive months. At the October 20, 2026 data cutoff, 39 adults and 10 adolescents had been treated; 31 patients had completed the follow-up required for the VF12 endpoint.

How Risto-Cel Works

Risto-cel uses a patient’s own CD34-positive hematopoietic stem and progenitor cells. Beam base-edits the promoter regions of the HBG1/2 genes, and the cells are administered through a hematopoietic stem cell transplant. The edit is designed to prevent the BCL11A transcriptional repressor from binding to the promoter without disrupting BCL11A expression, with the aim of increasing non-sickling and anti-sickling fetal hemoglobin and mimicking naturally occurring variants associated with hereditary persistence of fetal hemoglobin.

BEACON remains an ongoing open-label, single-arm, multicenter study in adults and adolescents with sickle cell disease and severe vaso-occlusive crises. Beam said the safety findings at the cutoff were consistent with previously reported BEACON data and with the known and intended effects of plerixafor use and cell collection, myeloablative conditioning with busulfan, autologous hematopoietic stem cell transplantation and underlying sickle cell disease.

Filing Timeline and Financial Capacity

Chief executive John Evans said the planned application “has the potential to be the first BLA for a base editing therapy.” Detailed pivotal results from the newly announced analysis are planned for presentation at a medical meeting in 2027.

Separately, Beam will present results from an earlier BEACON cutoff at the 68th American Society of Hematology meeting on December 12–15, 2026 in New Orleans. The oral presentation is scheduled for December 12 and was selected for ASH’s official press program. Beam’s November 4, 2026 notice said the presentation would include initial patient-reported outcomes covering physical function, pain, fatigue, emotional and social well-being and symptom severity.

Beam’s third-quarter report supplies the financial context for the filing plan. Cash, cash equivalents and marketable securities totaled $1.0 billion at September 30, 2026, compared with $1.2 billion at December 31, 2025. The third-quarter net loss was $134.4 million, while research and development expense was $110.1 million and general and administrative expense was $31.5 million, establishing the company’s recent quarterly spending scale as it approaches the planned filing.

Beam expects the September 30 liquidity, together with an additional $200 million anticipated from its Sixth Street facility, to fund operating expenses and capital expenditures into mid-2029 and support the company through a potential risto-cel launch, assuming the borrowing conditions are satisfied.

Any commercial launch remains contingent on FDA approval. Beam has interim efficacy and safety findings supporting its filing plan and a conditional runway beyond that timetable, but the planned submission and the agency’s review will determine whether risto-cel becomes an approved therapy.